This is an updated guideline for the diagnosis and management of allergic and nonallergic rhinitis, first published in 2007. It was produced by the Standards of Care
| INTRODUCTION
Allergic rhinoconjunctivitis (AR) remains the most common immunological disease in man and is still subject to under-recognition and poor management. This matters because AR significantly reduces quality of life (QOL), 1 interferes with both attendance and performance at school and work 2, 3 and results in substantial societal costs. 4 In addition, as the nose is the gateway to the respiratory tract, rhinitis is associated with symptoms in the eyes, 5 sinuses, 6 middle ear, 7 the nasopharynx and lower airways. 8 Both AR and non-allergic rhinitis (NAR) are risk factors for the development of asthma. 9 Rhinitis impairs asthma control 10, 11 and increases its costs. 11 All patients presenting with nasal symptoms require accurate diagnosis and appropriate treatment. These guidelines are intended to facilitate this.
Evidence for the recommendations was obtained using electronic literature searches using the primary keyword-rhinitis. Further interests were recorded.
The draft was reviewed by a lay person.
| DEFINITIONS/CLASSIFICATION
Rhinitis describes inflammation of the nasal mucosa but is clinically defined by symptoms of nasal discharge, itching, sneezing and nasal blockage or congestion. When the conjunctivae are also involved, the term rhinoconjunctivitis is more accurate. Involvement of the sinus linings in more widespread disease is known as rhinosinusitis.
Rhinitis has multiple phenotypes, usually divided into allergic, nonallergic and infective as well as mixed forms.
| Classification of Allergic Rhinitis (AR)
The WHO ARIA workshop "Allergic Rhinitis and its impact on Asthma" classification 14 of AR based on frequency and severity of symptoms has been validated. 15 Additionally clinical classification into seasonal and perennial rhinitis is useful in UK practice for diagnosis and allergen-specific therapy.
| Infective rhinitis
Any cause of congestion of the nasal mucosa can lead to occlusion of the sinus ostia, predisposing to acute rhinosinusitis and/or Eustachian tube dysfunction.
| Non-allergic rhinitis (NAR)
The numerous diagnoses in this category need to be borne in mind for patients with negative skin prick tests (SPTs). Table 1 summarizes the causes and disease patterns of NAR.
| EPIDEMIOLOGY
In the UK, rhinitis prevalence is 10.1% and 15.3% in 6-7 and 13-14 year olds respectively, 32 and 26% in UK adults. 33 Peak prevalence occurs in the 3rd and 4th decades, 34, 35 with some evidence for remission during adult life. 36 The prevalence in the UK and Western Europe has increased dramatically over the past 4-5 decades. 37, 38 Some studies suggest a plateau may have been reached, 32, [38] [39] [40] whilst others report continued increases since the 1990s. [41] [42] [43] There is a male preponderance before adolescence 41, [44] [45] [46] reversing post-adolescence. 35, 47, 48 World-wide, there appears to be a correlation between economic and industrial development and the prevalence of AR. 32, 49 Post-communist Eastern Europe has seen accelerating occurrence. 50 Local AR, confirmable only by nasal provocation, has been found to have a prevalence of over 25% in some centres. 51 A prevalence ratio of allergic to non-allergic rhinitis of 3:1 has been suggested. 52 Rhinitis is strongly associated with asthma: 74%-81% of asthmatics report symptoms of rhinitis. 53 Rhinitis, both allergic and non-allergic, is a strong risk factor for new-onset asthma. 54, 55 4 | AETIOLOGY Genetic predisposition is probably the most important factor in rhinitis development, but identification of specific susceptibility genes has proved difficult. Large scale genome-wide association studies (GWAS) have allowed identification of several candidate loci and genes for asthma and atopic dermatitis. [56] [57] [58] [59] To date, only one such GWAS has been carried out for AR. 60 Of note, classical genetic change (i.e change in DNA nucleotide sequence) is unable to account for the rapid increase in prevalence of AR seen in recent years, suggesting environmental factors (and possible gene-environment interactions) are important. Epidemiological evidence suggests smaller family size, urban environments and reduced exposure to infectious diseases is involved and appear to SCADDING ET AL.
| 857 have a particular effect during early life. [61] [62] [63] [64] Epigenetic modifications, such as DNA methylation, may be involved in the mechanism of gene-environment interactions in allergic diseases. 65 5 | ALLERGIC RHINITIS
| Pathophysiology
The basic mechanisms of AR are illustrated in Figure 1 .
Co-morbid associations of rhinitis (Table 2) .
AR-associated comorbid disorders can be subdivided into:
• other allergic diseases, particularly asthma • problems related anatomically to the nose: conjunctivitis, rhinosinusitis, hyposmia, middle ear problems, throat and laryngeal effects
• Sleep problems and secondary effects of symptoms on concentration, mood and behaviour
The most important co-morbidity is asthma: not only is rhinitis a risk factor for subsequent asthma but 80% of asthma sufferers according to ARIA have concomitant rhinitis, poor control of which is a risk factor for asthma exacerbations.
10,11,104-106
| NON-ALLERGIC RHINITIS (NAR)
This group consists of patients with symptoms of rhinitis but without any identifiable allergic triggers. It is a diagnosis of exclusion in patients negative for systemic IgE, when the many other causes of rhinitis have 
| Pathophysiology
At least two subgroups exist: one with nasal inflammation on histology, 107 the other without inflammation or local IgE production. 108 The former includes local allergic rhinitis 109 and non-allergic rhinitis with eosinophilia (NARES). A proportion of patients within this latter group are aspirin/NSAID sensitive. 110 There is evidence that some patients with apparently non-allergic rhinitis share similar histologic mucosal features as those with allergic rhinitis characterized by increased numbers of mast cells and eosinophils and produce local IgE, 107, 111, 112 Patients with non-inflammatory type rhinitis are thought to suffer from dysfunction of the autonomic nerve supply to the nasal mucosa.
67,113
| Occupational rhinitis
Occupational rhinitis, which can be allergic or non-allergic, describes abnormalities of the nasal mucosa mediated by airborne substances in the work environment. It is distinct from work-exacerbated rhinitis, which refers to individuals with pre-existing rhinitis who experience an exacerbation of symptoms due to workplace exposures. Over 300 agents can cause occupational rhinitis, and these are the same as those which can induce occupational asthma. 114 HMW agents are protein allergens derived from plants or animals, for example, flour, latex, laboratory animals and evidence of sensitization are usually seen on skin testing or serum-specific IgE. 115 LMW agents cause mucosal inflammation either via airway immune sensitization, (e.g di-isocyanates and glutaraldehyde) or via irritant exposures (e.g chlorine and ammonia). Occupational rhinitis is three times more frequent than occupational asthma; the two conditions frequently occur together. 116, 117 The early identification of a causative occupational agent and the avoidance of exposure are important for the prevention of progression to occupational asthma [118] [119] [120] [121] (Grade B) .
Diagnosis is based on a detailed history, including symptom diary review, improvement of nasal symptoms during weekends and holidays, skin prick testing and measurement of specific IgE when appropriate.
Latex is a cause of both occupational rhinitis and asthma.
Prevention of latex allergy by removing powdered gloves or substituting non-latex ones is essential. All healthcare environments should have a latex policy 119, 122 (Level of evidence=2+ and 4; Grade of recommendation=D, C for adults and children with perennial rhinitis or adults and children with latex allergy).
F I G U R E 1
Immunological mechanisms of Allergic Rhinitis. Sensitized patients with allergic rhinitis have IgE antibodies for specific allergen(s) bound to receptors on the surface of mast cells. On re-exposure to the specific allergen(s), cross-linking of adjacent IgE molecules occurs, and mast cell degranulation results. Pre-formed mediators such as histamine stimulate sensory nerve endings within seconds, causing itch and sneezing, and promote dilatation of local vasculature and glandular secretion, causing obstruction and rhinorrhoea, respectively. Newly synthesized mediators, including leukotrienes, as wells as chemokines and cytokines contribute to a delayed eosinophil and Th2 T cell predominant inflammation, the late-phase response, characterized by nasal obstruction and hyperreactivity. 66 Additional mechanisms are likely to be relevant. These include neuro-immune interactions, such as release of neuropeptides (substance P, calcitonin gene-related peptide) and neurokinins from sensory nerve endings in response to inflammatory mediators. 67 The role of the epithelium, particularly its interaction with newly defined type 2 innate lymphoid cells (ILC2), has been scrutinized in murine asthma and allergy models 68, 69 Some co-morbidities appear as consequences of AR, for example, concentration and sleep problems, others co-exist with it as a consequence of underlying allergy, for example atopic dermatitis. The mechanism of the association between asthma and rhinitis is uncertain, but the tendency for asthma to succeed rhinitis, the demonstration that nasal allergen challenge in AR gives lower respiratory tract inflammation and the prevention of progression of AR to asthma by allergen immunotherapy suggest that the asthma is consequential in individuals in whom rhinitis is the initial manifestation of atopic disease.
| DIAGNOSIS OF RHINITIS

| History
A detailed history is required, including seasonality (pollen, moulds), indoors/outdoors location (dust mite, the presence of house pets), work location (occupational), improvement of holidays and, relationship to potential triggers which can impact on the patient's quality of life. Symptoms of sneezing, nasal itching, itching of the palate are more likely to lead to allergic rhinitis.
| Rhinorrhoea
Rhinorrhoea is either anterior, posterior or both.
• Clear-infection unlikely if continuously clear, although secretions are clear early in viral rhinitis
• Unilateral-is uncommon and cerebrospinal fluid (CSF) leak should be excluded 123 • Coloured
yellow-allergy or infection; green-usually infection; blood tinged
2. unilateral-tumour, foreign body, nose picking or misapplication of nasal spray 3. bilateral-misapplication of nasal spray, granulomatous disorder, bleeding diathesis, infection, nose picking.
| Nasal obstruction
• Can be partial or complete; severity often correlates with systemic manifestations
• Bilateral-most likely rhinitis or nasal polyps but maybe septal (sigmoid) deviation
• Unilateral-usually septal deviation but also consider foreign body, antrochoanal polyp and tumours
• Alternating-due to rhinitis exposing the nasal cycle 124 
| Nasal crusting
Severe crusting especially high inside the nose is an unusual symptom in rhinitis and requires further investigation. Consider: chronic rhinosinusitis, 125 nose picking, granulomatous polyangiitis, sarcoidosis or other vasculitides, (particularly if crusting is associated with bleeding), cocaine abuse, ozaena (wasting away of the bony ridges and mucous membranes inside the nose), non-invasive ventilation. Topical steroids rarely cause crusting.
| Eye symptoms
Include intense itching, redness and swelling of the white of the eye, watering, Lid swelling and (in severe cases) periorbital oedema, which can be aggravated by eye rubbing.
| Lower respiratory tract symptoms
• Cough, wheeze, shortness of breath-can occur with rhinitis alone since bronchial hyper-reactivity can be induced by upper airway inflammation. [126] [127] [128] Disorders of the upper and lower respiratory tract often coexist:
• 80% of asthmatics have rhinitis-see section on rhinitis and asthma 7.7 | Other symptoms
• Snoring, sleep problems, repeated sniffing, nasal intonation of the voice
• Pollen-food syndrome is triggered by ingestion of cross-reacting antigens in some fruits, vegetables and nuts 129 • A proportion of patients suffering from allergic (mainly seasonal)
rhinitis have an associated nasal hyper-reactivity which is generally not recognized/treated
| Family history
A diagnosis of allergic rhinitis is more likely when rhinitis is seasonal, or with a family history of AR. However, it can arise de novo.
| Social history
Consider pets or other contact with animals, occupation or schooling.
| Drugs
A number of drugs can cause or aggravate rhinitis symptoms, and therefore, a drug history should include details of the use of alphaand beta-blockers and other anti-hypertensives, aspirin and other non-steroidal anti-inflammatory drugs, oral contraceptives as well as topical sympathomimetics (see Table 1 ). It is also important to enquire about the efficacy of previous treatments for rhinitis and details of how they were used and for how long. • Yellow submucosal nodules with a cobblestone appearance suggest sarcoidosis.
131
• Crusting and granulations raise the possibility of vasculitis • Septal perforation may occur after septal surgery or due to chronic vasoconstriction (cocaine, alpha agonists), granulomatous polyangiitis, anti-phospholipid antibody syndrome and nose picking
• Throat examination-cobblestoned lymphoid hyperplasia, postnasal drip
| Nasal endoscopy
Used in specialist centres to examine both the anterior and posterior parts of the nasal cavity this is more specific than rhinoscopy and alters the diagnosis in up to a fifth of patients with nasal disease. 132 
| INVESTIGATIONS
Allergen-specific IgE can be detected with skin prick tests (SPTs) or by serum immunoassay.
| Skin prick tests (SPT)
• • Full blood count (FBC) and differential white cell count, C-reactive protein (CRP), immunoglobulin profile, microbiological examination of sputum and sinus swabs when chronic infection is suspected
• Thyroid function tests in unexplained nasal obstruction • Nasal secretions-asialotransferrin for CSF identification • Urine toxicology when cocaine abuse is suspected
| Olfactory tests
The University of Pennsylvania Smell Identification Test (UPSIT) is well validated, and can be helpful when there is suspicion of malingering, 135 it is accepted for legal cases.
| Cytology
The techniques for obtaining cells for cytology in secretions, lavage, scraping, cotton buds or brushings have not been standardized, nor have the criteria for evaluating cell counts. 136 Nevertheless the presence of eosinophils implies inflammation and may be helpful in predicting response to corticosteroids.
137,138
| Exhaled nitric oxide (eNO)
Exhaled nitric oxide (FeNO=fractional exhaled nitric oxide) measurement can be useful clinically in the diagnosis and monitoring of asthma. Normal levels are less than 20 ppb, but become elevated in eosinophilic lower respiratory tract inflammation. 139 9.7 | Nasal NO Levels are complex as there are two sources of NO: sinuses and nasal epithelium. However, very low levels (<100 ppb) indicate the likelihood of primary ciliary dyskinesia, but can also be observed in cystic fibrosis and in sinus obstruction caused by large polyps. NO measurements are restricted to specialist centres.
| Radiology
Radiology is not routinely recommended for simple rhinitis. However, when rhinosinusitis or nasal polyposis is suspected, especially non-responsive to medical therapy, CT scan is helpful.
| Nasal challenge
It is not routinely available outside specialist centres; there is no standardized methodology and asthmatic reactions can occur. It may be useful to confirm aspirin sensitivity or in occupational allergic rhinitis, where there is discrepancy between history and when there are potentially important occupational implications.
| Objective measures of nasal airway
Objective measurements of the nasal airway are not made in routine clinical practice but can be useful when allergen or aspirin challenges are undertaken and may be helpful when septal surgery or turbinate reduction are being contemplated.
| Tests for asthma
Measurements of lung function should be considered in all patients with persistent rhinitis.
| ENT referral
Patients with unilateral symptoms, heavily blood stained discharge or pain, require ENT referral. Those with nasal blockage unrelieved by pharmacotherapy or structural abnormalities, such as septal deviation, sufficient to render nasal therapy difficult should be seen by a surgeon.
10 | TREATMENT
| Allergen avoidance
Allergen avoidance clearly works in seasonal allergic rhino-conjunctivitis: hayfever sufferers are symptom-free outside the pollen season. For patients with house dust mite-sensitive AR the situation is complicated by the difficulties of reducing exposure to mites in the home. A systematic review of trials of mite allergen avoidance in rhinitis concluded that trials are generally small and of poor methodological quality and meta-analysis could not be performed. 140 Large studies of a combination of strategies to reduce exposure to dust mites have not been conducted but should probably include measures to reduce mites in cars, at school and work (see Figure 2) .
Evidence from randomized studies is summarized in Table 3 .
For occupational AR complete avoidance of exposure to the causal agent is recommended. 115 Irritants such as smoke, traffic pollution can worsen rhinitis symptoms and should be avoided, where possible.
In a DBRPC study, the application of a cellulose powder (Nasaleze TM ) three times daily resulted in significant reductions in severity scores for sneezing, runny nose, stuffy nose and symptoms from eyes and lower airways with no clinically significant adverse effects (Grade B).
141
Interventions that may help to reduce symptoms during the pollen season include patients wearing sunglasses (Grade C), 142 nasal filters, 121 balms and ointments applied to the nose. 143 Other practical/common sense measures that may reduce exposure to pollen are summarized in Table 3 but have not been tested in studies.
| Pet allergens
For patients with AR sensitized to and symptomatic on contact with pets such as cats, dogs and horses, avoidance of the animal should be advised. For those who wish to keep pets to which they are sensitized, there is limited information from randomized studies on which to base recommendations 144 HEPA filters alone do not seem useful for cat allergic patients with cats. 145 Cat allergen exposure can be reduced using temperature-controlled laminar airflow treatment, 145 and although this treatment has shown to improve asthma-related quality of life, this has not been tested for rhinitis. | 867
| Saline irrigation
Isotonic saline irrigation in both adults and children with allergic rhinitis was well tolerated, 148 inexpensive, easy to use with no evidence of adverse effect to health with regular use. 149, 150 It has a small beneficial effect in symptom reduction and may reduce the amount of pharmacotherapy needed (Grade B).
| Carbon dioxide washing
The use of a ten second burst of carbon dioxide from a pressurized Check use, concordance, dose F I G U R E 2 Rhinitis treatment algorithm. Additional therapies can be accomplished using two different medications, or a combination treatment in one device. There is, as yet, no comparative evidence on which to base this choice; however, concordance appears more likely when the regime is simple stepwise pharmacotherapeutic approach should be undertaken. A combination of treatments is often needed for more severe disease, and it is here that the option of immunotherapy should also be considered ( Figure 3 ).
| Antihistamines
Antihistamines are available as oral, intranasal and ocular preparations.
All demonstrate clinical efficacy. It is important to use a drug with the least adverse effect and that is considered safe for the current situation (i.e such as pregnancy, breastfeeding).
Second-generation antihistamines are long acting and are largely non-sedating and have no clinically significant anti-cholinergic activity at therapeutic doses, although there is variation in individual susceptibility to such effects. 154 
| Oral H1-antihistamines
Reduce mean daily rhinitis symptom scores (in absolute terms) by an estimated 7% versus placebo 155 and can significantly improve quality of life.
156,157
They act predominantly on neurally mediated symptoms of itch, sneeze and rhinorrhoea and have only a modest effect on nasal congestion. [158] [159] [160] [161] [162] [163] [164] Additionally, they reduce histamine driven symptoms such as itch 165 at sites other than just the nose such as conjunctiva, palate and skin. [166] [167] [168] They should be used regularly rather than "as needed" use in persistent rhinitis. 169, 170 Acrivastine has the fastest onset of action, but needs to be used 8 hourly; fexofenadine is the least sedating oral antihistamine with a wide therapeutic index.
| Adverse effects
First-generation antihistamines are less useful due to sedation and cognitive impairment, which can worsen driving and examination results already impaired by rhinitis, 171, 172 Their use is not recommended. Antihistamines with an anticholinergic effect are associated with development of dementia. 173 
| Second-generation antihistamines
Terfenadine and astemizole were implicated in deaths from ventricular fibrillation via QT interval prolongation. 174 Ebastine and mizolastine also need to be used with caution in those with cardiac risk factors, 175 but even cetirizine, desloratadine, diphenhydramine, fexofenadine, loratadine were possibly associated with cardiac arrhythmias in a single large European pharmacovigilance study. 176 Interaction with other medications is rare other than for mizolastine with certain anti-arrhythmics, antibiotics and beta-blockers leading to an increased risk of arrhythmia. Rupatadine should not be coprescribed with known CYP3A4 inhibitors. 177 
| Place in therapy
• First-line therapy for mild=to-moderate intermittent and mild persistent rhinitis
• Addition to intranasal steroids for moderate/severe persistent rhinitis uncontrolled on topical intranasal corticosteroids alone, particularly when eye symptoms are present. [178] [179] [180] Evidence for this combination is less good than for the addition of intranasal antihistamine to topical intranasal corticosteroids in a guinea-pig model. There is a rapid onset of action (15 minutes), faster than oral antihistamines, 185 thus, the drug can be used on demand as rescue therapy for symptom breakthrough. Continuous treatment is, however, more clinically effective than on demand use. 186 They can be effective in patients who have previously failed oral antihistamines. 187 Treatment with both an intranasal and oral antihistamine confers no additional advantage in alleviating nasal symptoms. 187 They are less effective than an intranasal steroid in relieving the symptoms of allergic rhinitis. 188 Adverse effects include local nasal irritation and taste disturbance with Azelastine (dysgeusia). Azelastine nasal spray is the only available intranasal antihistamine in the UK.
T A B L E 4 Pharmacotherapy effects on individual rhinitis symptoms (adapted from 152)
| Place in therapy
This is the first line of therapy for mild-to-moderate intermittent and mild persistent rhinitis.
Intranasal steroids used for moderate/severe persistent rhinitis which are not controlled on topical intranasal corticosteroids alone.
| CORTICOSTEROID THERAPY
| Intranasal corticosteroids (INS)
Topical corticosteroids are the mainstay of anti-inflammatory intervention in AR. Factors which need consideration are systemic drug bioavailability, safety and cost. 189 Ease of device use may influence concordance. INS reduces all symptoms of rhinitis by about 17% more than placebo, with a variable effect on associated allergic conjunctivitis. 190, 191 Meta-analysis shows that INS is superior to oral antihistamines or leukotriene receptor antagonist alone on all aspects of allergic rhinitis 155, 192 (Grade Ia).
Unlike other treatments, INS reduce nasal congestion. 192 Onset of action is 6-8 hours after the first dose, clinical improvement may not be apparent for a few days and maximal effect may not be apparent until after two weeks. 192 Starting treatment two weeks prior to a known allergen season improves efficacy. 193 Similar clinical efficacy for all INS, but bioavailability varies considerably (see Figure 3 ).
Systemic absorption negligible with mometasone furoate, fluticasone furoate and fluticasone propionate and these preparations are favoured for children. Systemic absorption is modest for the remainder, and high for betamethasone which should be used short-term only. 194, 195 
| Adverse events
Local nasal irritation, sore throat and epistaxis affect around 10% of users. Benzalkonium chloride is used as a preservative in several topical corticosteroids, and may irritate the nose, but does not adversely affect mucociliary clearance. 196 In patients with nasal irritation symptoms such as burning, for example, a trial with a benzalkonium free preparation, for Hypothalamic-pituitary axis suppression may occur when multiple sites are treated with topical corticosteroids in the same person (e.g skin, nose and chest). 197 If corticosteroids are used in multiple sites, then a low bioavailability preparation should be favoured.
Raised intra-ocular pressure has been described with INS 198 thus limiting its use in patients with predisposition to high ocular pressure/glaucoma is important.
| Place in therapy
First-line therapy for moderate-to-severe persistent symptoms. 13 | COMBINATION THERAPY
| INS and oral preparations
INS demonstrate similar or greater efficacy to an oral antihistamine plus a leukotriene receptor antagonist 199, 200 (see Appendix A2).
| INS and topical H1-antihistamine combination
Currently available as a combination spray containing azelastine and fluticasone propionate (FP), dymista leads to greater symptom improvement than using either agent alone in SAR (Grade A). 201 All symptoms of allergic rhinitis were significantly improved with onset of action by 30 minutes. 202 The combination approach leads to clinical improvement of symptoms days earlier than seen with azelastine or FP monotherapy. 201 Ocular symptoms of allergy were better treated with the combination spray rather than FP or azelastine alone. 202 Efficacy over FP is demonstrated in perennial allergic rhinitis. 203 
| Adverse effects
The main side-effect is the bitter taste of azelastine, which is experienced by a small proportion of users.
| Place in therapy
Combination of topical AH with INS should be used in patients when symptoms remain uncontrolled on AH or INS monotherapy or on a combination of oral AH plus INS.
| Systemic glucocorticoids
There are no trials of oral steroid use and efficacy in AR, although there is grade A evidence in chronic rhinosinusitis with nasal polyposis where inflammation is more severe. Use is rarely indicated in the management of allergic rhinitis except for:
| SEVERE NASAL OBSTRUCTION
In order to obtain control, short-term rescue medication is used during severe exacerbation despite compliance on conventional pharmacotherapy. It is important to ensure intranasal steroid therapy is coadministered alongside oral steroids with or without a short-term decongestant spray to allow intranasal drug penetration (see below).
There is no definite consensus on the dose and duration of systemic steroid therapy. A suggested regime for adults is 0.5 mg per kg for 
| Injectable corticosteroids
Injected preparations are not recommended as compared to other available treatments the risk-benefit profile for intramuscular corticosteroids is poor.
204,205
| Intranasal decongestants
Topical formulations allow relief of nasal congestion via vasoconstriction within minutes, faster and with greater impact than intranasal steroids. 206, 207 A decongestant spray may allow delivery of intranasal drugs beyond the inferior turbinates. For example, oxymetazoline and fluticasone furoate when used together further improved nasal congestion more than either alone. 207 There is no licensed INS plus decongestant combination preparation in the UK at present.
| Adverse events
Only short-term use (generally fewer than 10 days) is recommended as a paradoxical increase in nasal congestion secondary to rebound vasodilatation (rhinitis medicamentosa) can occur. 208 The risk of this occurrence increases with duration of 3-5 days maximum. 209, 210 Intranasal decongestants are less likely to lead to rhinitis medicamentosa when used short-term and alongside an intranasal steroid.
210
They can also cause nasal irritation and may increase rhinitis.
| Place in therapy
• Eustachian tube dysfunction when flying (evidence level D)
• To increase nasal patency before douching (Grade D) or intranasal administration of nasal steroids 211 
| Oral decongestants (pseudoephedrine)
• Weakly effective in reducing nasal obstruction 212 and have many side-effects, so are not recommended. 213 
| Anti-leukotrienes
These have a therapeutic profile similar to antihistamines, with efficacy comparable to loratadine in seasonal allergic rhinitis, 214 and are less effective than topical nasal corticosteroids. [214] [215] [216] [217] The response is less consistent than that observed with antihistamines. [218] [219] [220] LTRAs reduce the mean daily rhinitis symptom scores by 5% more than placebo. 155 Combination of anti-leukotriene plus antihistamine has no advantage over either drug used alone [221] [222] [223] [224] and is not any more effective than topical corticosteroid alone. 198, 224 Anti-leukotrienes may have a place in asthma patients with seasonal allergic rhinitis. 226 
| Adverse events
| Place in therapy
Montelukast is licensed in the UK for those with seasonal allergic rhinitis who also have concomitant asthma (UK licence for age > 6 months; Zafirlukast UK licence>12 years).
| TOPICAL ANTI-CHOLINERGIC
| Ipratropium bromide
Used three times daily it decreases rhinorrhoea (particularly if neurogenic rather than inflammatory origin) but has no effect on other nasal symptoms. 19, [229] [230] [231] Regular use may be effective as an "add-on" for allergic rhinitis when watery rhinorrhoea persists despite topical steroids and antihistamines 229,232
| Adverse events
Dry nose and epistaxis, 145 systemic anti-cholinergic effects are unusual. 233, 234 Caution is advised in the elderly in whom periodic revisions of its requirement may have to be instigated.
| Place in therapy
Patients with watery rhinorrhoea despite compliance with INS or INS plus antihistamine
| CHROMONE S (SODIUM CROMOGLYCATE (= CROMOLYN) AND NEDOCROMIL SODIUM)
Sodium cromoglycate and nedocromil sodium inhibit the degranulation of sensitized mast cells, inhibiting the release of mediators. 235 Sodium cromoglycate is weakly effective in rhinitis with some effect on nasal obstruction. 236, 237 The spray needs to be used several times (3-49 up to 69) per day.
| Adverse events
Generally very well tolerated (including in pregnancy) but these include local irritation, taste disturbance and headache.
| Place in therapy
• Children and adults with mild symptoms only and sporadic problems in season or on limited allergen exposure. 238 Useful for individuals unable to take other medications, for example pregnant females.
• Cromoglycate and nedocromil eye drops are useful in conjunctivitis as topical therapy.
236,239
| OCULAR THERAPY
Sunglasses reduce eye symptoms, 142 but as these can occur reflexively secondary to nasal inflammation complete protection is impossible. The ocular manifestations of seasonal rhinoconjunctivitis can often be suppressed by oral antihistamines, usually H1 receptor antagonists, and by intranasal agents, including corticosteroids, antihistamines and combination products. However, they are often better treated using topical eye drops. Mast cell stabilisers such as sodium cromoglycate, nedocromil sodium and lodoxamide are generally effective and safe. 239 Antihistamines such as azelastine, emedastine and epinastine may be preferred by some patients. 240 A drug with both mast cell stabilising and antihistaminic properties, olopatadine, is often effective and well tolerated, and has the advantage of twice daily application, which particularly suits contact lens wearers.
Some patients find that tear supplement drops ("artificial tears") pro- 
| IMMUNOTHERAPY
Allergen immunotherapy can improve symptoms, reduce medication requirements and improve quality of life.
241-243
| Subcutaneous injection immunotherapy (SCIT)
SCIT is effective for both seasonal rhinitis due to pollens (Cochrane meta-analysis 244 evidence level 1++) and perennial rhinitis due to house dust mite, 245 evidence level 1+). There are few randomized controlled trials of immunotherapy for cat allergy, 246, 247 (level 1) SCIT requires weekly up-dosing regimens followed by 4-6 weekly maintenance injections for 3-5 yr. Pre-seasonal SCIT is effective for pollen allergy. In view of the risk of systemic side-effects SCIT should only be given in specialist clinics by trained personnel with immediate access to adrenaline and resuscitation facilities. 248 
| Sublingual Immunotherapy (SLIT)
SLIT has emerged as an effective and safe alternative for the treatment of allergic rhinitis with/without seasonal asthma 242 due to grass pollen [249] [250] [251] [252] [253] [254] [255] ragweed, 256, 257 evidence level 1++) and house dust mite(evidence level 1).
249,258
Sublingual immunotherapy is well tolerated, with side-effects largely confined to local itching and swelling in the mouth and throat. After supervision of the first dose by the prescribing physician with a onehour period of observation, SLIT is self-administered daily at home.
SLIT has an excellent safety record, although there are case reports of systemic reactions and of eosinophilic oesophagitis, but no deaths have been reported. Oral antihistamine given prior to SLIT initiation and for the first two weeks of the course of therapy can reduce local oral irritation (level D).
| Long-term benefits
Immunotherapy is the only treatment that can modify the course of allergic rhinitis, with long-term remission following discontinuation. [259] [260] [261] Subcutaneous immunotherapy in children with seasonal rhinitis reduces progression to asthma, an effect that persisted for 10 years. 262 Immunotherapy may prevent development of new sensitizations. 
| Intranasal ipratropium
This is effective for watery rhinorrhoea (level 1b; Bronsky et al. 234 ).
266-278
| Topical capsaicin
Desensitization reduced symptoms for several months in non-allergic, non-infectious rhinitis, NINAR.
279-281
| Topical corticosteroids
Topical corticosteroids have an effect in skin prick test-negative rhinitis patients (level 1b), probably on those with underlying inflammation, since studies give variable results, [282] [283] [284] [285] [286] and relief was limited in subjects with low levels of nasal eosinophils in a recent study. 287 
| Topical nasal antihistamines
Azelastine and olopatadine [288] [289] [290] [291] (level 1b) and a combination of azelastine with fluticasone (level 3) reduced symptoms in skin prick test-negative patients over one year. 203 Decongestants and oral antihistamines are ineffective.
| Montelukast
It has not been formally trialled in NAR but low quality studies 224 suggest a possible effect in SP-negative patients.
TRPV1 was considered a prime target for neurogenic rhinitis therapy, but a recent study proved negative when cold dry air challenges were used, 292 but antagonism did reduce the response to capsaicin. 293 
| Aspirin desensitization
This may be effective in those with aspirin-sensitive NAR, but should be preceded by nasal or oral aspirin challenge to establish the diagnosis. [294] [295] [296] [297] A suggestion for NAR therapy is given in Figure 5 .
| SURGERY
Surgery is offered in only a minority of cases. The indications for surgical intervention are as follows:
1. Anatomical variations of the septum with functional relevance. There are no well-conducted (prospective and randomized) studies supporting the use of coblation, laser or surgery to the inferior turbinates in patients with rhinitis which demonstrate benefit, supported by objective measurements, other than in the short-term.
Studies of this nature show that surgery to the inferior turbinate does not confer any lasting benefit. 299 If in future trials of surgery are to be done it would seem that, in the first instance, they should be limited to patients who have failed to respond to medical treatment given the evidence that is currently available for the benefit that concordant medical treatment provides in the majority of patients.
| ASSESSMENT OF RHINITIS CONTROL
Since 2001, the ARIA patient classification system for allergic rhinitis has been used in both clinical and research settings. It focuses on patient symptoms, their time patterns (either "intermittent" or "persistent") and their severity ("mild" vs "moderate/
severe") and is a simple and quick to administer tool ( Figures 6, 7, 8) .
In response to a World Health Organisation endorsed trend, disease control rather than severity is considered a preferable metric to measure and monitor. and patients benefit from a multidisciplinary approach. 310 Rhinitis in pregnancy impacts negatively on quality of life, especially during the third trimester and women with pre-existing allergic rhinitis are more severely affected. 314 Informing the patient that pregnancyinduced rhinitis is a self-limiting condition is often reassuring.
Women developing rhinitis during pregnancy are more likely to deliver female babies, 315 and children of mothers developing rhinitis in early pregnancy are more likely to develop rhinitis themselves. 316 During pregnancy, most medications cross the placenta, and should only be prescribed when the apparent benefit is greater than the risk to the foetus. 317 Nasal lavage is safe and effective in pregnant women, reducing the need for antihistamines. 318 Chromones have not shown teratogenic effects in animals and are the safest drug recommended in the first 3 months of pregnancy, although they require multiple daily administrations. The safety of nasal steroids in pregnancy has not been established through clinical trials.
Only minimal amounts of steroid pass into the bloodstream after using a nasal spray and it is good practice to treat with "tried and tested" drugs. 317 Beclomethasone, FP and budesonide have good safety records and are widely used in pregnant asthmatic women of these fluticasone has least systemic bioavailability when used nasally. 324 and cetirizine appear safer with low levels found in breastmilk. 325 The lowest dose should be used for the shortest duration.
319-321
| RH INITIS IN CHILDREN
Acute viral rhinitis is common and usually easy to distinguish. It increasing to 27% of 18 year olds( Figure 6 ). 327 Allergic rhinitis in early childhood is a risk factor for developing asthma in later childhood and adulthood. 328, 329 It has a significant impact on children's quality of life and can have detrimental effects on sleep, behaviour, school performance and family dynamics. 171 It often presents alongside other atopic disorders, asthma and eczema and food allergy. Its presentation may be influenced by co-morbidities, such as conjunctivitis, impaired hearing, rhinosinusitis, sleep problems and pollen-food syndrome 330 ( Figure 7 ).
Entopy (local allergic rhinitis), diagnosed by nasal allergen challenge, is found in children (level D).
331,332
• The approach to diagnosis in children is similar to that in adults:
history, skin prick test and anterior rhinoscopy
• Entopy (local allergic rhinitis), diagnosed by nasal allergen challenge is found in this age group (level D) 331, 333 • Therapy of rhinitis in children is based on the same principles as in adults; however, it should take into account specific paediatric needs, such as acceptability, practicality for both children and parents and concern for potential side-effects (Figure 8) • Nasal saline irrigation is effective in the treatment of AR in children 149, 334 • Brief concomitant use (3 days) of topical decongestants can be helpful in children with significant nasal blockage to aid introduction of topical nasal steroid therapy
• Recommendation for continuous use of intranasal steroids can often create anxiety in parents; intranasal steroids with low bioavailability have a better safety profile at recommended doses and should be used in preference (Figure 4) 335,336
• It is advisable to monitor growth in children, especially if they are receiving steroids by multiple routes 335 (see also Table 3) • A short course (3 to 7 days) of oral corticosteroids may be required in severe cases. Intramuscular steroids have no role in the treatment of AR
• Immunotherapy is recommended in subjects who have not adequately responded to maximal pharmacotherapy; the potential added benefit in disease prevention should be considered when treating children 337, 338 • Education on therapy plays an important role on treatment outcome. Both children and carers should be provided with the relevant information and appropriate training 339 • Otitis media with effusion and/or adenoidal hypertrophy may be associated with AR; the mechanistic link is unknown. Some studies suggest benefit to these common paediatric conditions from rhinitis treatment 340 
| QUALITY OF LIFE QUESTIONNAIRES FOR RHINITIS
The burden of rhinitis for an individual patient can be estimated This guideline is the revised edition for the management of allergic and non-allergic rhinitis. Adherence to this guideline does not constitute an automatic defence for negligence, and conversely nonadherence is not indicative of negligence. It is anticipated that this guideline will be reviewed 5 yearly.
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